Pharvaris (NASDAQ:PHVS) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 30.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,734 shares of the company's stock after purchasing an additional 14,838 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.12% of Pharvaris worth $1,222,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares during the period. Geode Capital Management LLC boosted its holdings in Pharvaris by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after buying an additional 1,356 shares in the last quarter. Deutsche Bank AG boosted its holdings in Pharvaris by 13.0% during the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after buying an additional 2,087 shares in the last quarter. JPMorgan Chase & Co. grew its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the fourth quarter valued at about $64,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PHVS shares. Cantor Fitzgerald decreased their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. Finally, Guggenheim started coverage on Pharvaris in a research report on Wednesday. They set a "buy" rating and a $32.00 target price on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pharvaris has a consensus rating of "Buy" and a consensus target price of $36.20.

Pharvaris Stock Performance

Pharvaris stock traded down $1.07 during midday trading on Wednesday, reaching $17.05. 37,761 shares of the company were exchanged, compared to its average volume of 75,237. The firm's 50-day simple moving average is $15.70 and its 200-day simple moving average is $17.00. Pharvaris has a 1 year low of $11.51 and a 1 year high of $25.50. The company has a market capitalization of $891.54 million, a price-to-earnings ratio of -6.09 and a beta of -2.86.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, analysts forecast that Pharvaris will post -2.71 EPS for the current fiscal year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.